Primary progressive aphasia (PPA) is a rare type of neurodegenerative disease that can severely impact an individual’s ability to communicate and/or comprehend language. As this is a rare condition, little research has been conducted leaving gaps in our understanding of this disease. Through our research, we aim to identify biomarkers that are capable of predicting the natural course and the underlying pathology in this clinically and pathologically heterogeneous condition. To achieve this, we complete annual assessments on patients which include comprehensive neuropsychological tests, CSF examination to measure amyloid and tau levels, and brain MRI.